Skip to main content
Log in

Behandlung chronisch entzündlicher Darmerkrankungen bei Kindern und Jugendlichen

Therapiekonzepte einschließlich Biologika

Treatment of chronic inflammatory intestinal diseases in children and adolescents

Therapy concepts including biologics

  • Schwerpunkt
  • Published:
Der Gastroenterologe Aims and scope

Zusammenfassung

Die Behandlung von Kindern und Jugendlichen mit chronisch entzündlichen Darmerkrankungen (CED) ist aufgrund einer schmalen wissenschaftlichen Basis für Therapieentscheidungen nach wie vor problematisch. Daten aus Studien bei Erwachsenen sind mit Vorbehalt zu werten. Biologika (TNF-α-Blocker) haben die CED-Therapie bereichert. Studiendaten zeigen bei Kindern einen steroidsparenden und das Wachstum optimierenden Effekt. Bei Versagen einer Standardtherapie sowie bei extraintestinalem Befall und Fisteln werden TNF-α-Blocker zunehmend primär oder früh im Therapiekonzept eingesetzt. Bei Kindern mit schwerer Colitis ulcerosa sind TNF-α-Blocker trotz fehlender Zulassung eine Alternative zu bisherigen Immunsuppressiva.

Abstract

The treatment of children and adolescents with chronic inflammatory intestinal diseases is still problematic because of a narrow scientific basis for therapeutic decision-making. Data from studies involving adults must be evaluated with caution. Biologics, such as TNF-α blockers have been approved for the induction and maintenance of remission in moderate-to-severe pediatric Crohn’s disease that is unresponsive to conventional therapy. Data from studies on children show a steroid-saving and growth optimizing effect. Regularly scheduled maintenance therapy is recommended. Inflixmab is also a therapeutic alternative in children with severe ulcerative colitis. Adalimumab may be used in cases of side-effects or loss of response.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5
Abb. 6

Literatur

  1. Beaugerie L, Brousse N, Bouvier AM, CESAME Study Group et al (2009) Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374: 1617–1625

    Article  PubMed  CAS  Google Scholar 

  2. Borelli O, Bascietto C, Viola F (2004) Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig Liver Dis 36: 342–347

    Article  Google Scholar 

  3. Buderus S (2004) Chronisch-entzündliche Darmerkrankungen: Medikamentöse Therapie im Kindes- und Jugendalter. Monatsschr Kinderheilk 152: 133–44

    Article  Google Scholar 

  4. Colombel JF, Sandborn WJ, Reinisch W, SONIC Study Group et al (2010) Infliximab, Azathioprine, or combination therapy for Crohn’s disease. N Engl J Med 362: 1383–1395

    Article  PubMed  CAS  Google Scholar 

  5. Crandall W, Hyams J, Kugathasan S et al (2009) Infliximab therapy in children with concurrent perianal Crohn disease: Observations from REACH. J Pediatr Gastroenterol Nutr 49: 183–190

    Article  PubMed  CAS  Google Scholar 

  6. Cucchiara S, Latiano A, Palmieri O et al (2007) Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. J Pediatr Gastroenterol Nutr 44: 171–179

    Article  PubMed  CAS  Google Scholar 

  7. Carpi JM de, Pociello N, Varea V (2010) Long-term efficacy of adalimumab in paediatric Crohn‘ disease patients naïve to other anti-TNF therapies. J Crohn’s Colitis 4: 594–598

    Google Scholar 

  8. Zoten E de, Mamula P (2008) What are the guidelines for using biologics in pediatric patients? Inflamm Bowel Dis 14: S259–S261

    Article  Google Scholar 

  9. Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M (2005) Infliximab efficacy in pediatric ulcerative colitis. Inflamm Bowel Dis 11: 213–218

    Article  PubMed  Google Scholar 

  10. Escher JC, Taminiau JAJM, Nieuwenhuis EES, Buller HA, Grand RJ (2003) Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm Bowel Dis 9: 34–58

    Article  PubMed  Google Scholar 

  11. Hyams J, Crandall W, Kugathasan S, REACH Study Group et al (2007) Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn’s disease in children. Gastroenterology 132: 863–873

    Article  PubMed  CAS  Google Scholar 

  12. Hyams J, Lerer T, Griffiths A, Pfefferkorn M et al (2009) Long-term outcome of maintenance infliximab therapy in children with Crohn’s disease. Inflamm Bowel Dis 15: 816–822

    Article  PubMed  Google Scholar 

  13. Hyams J, Lerer T, Griffiths A, Pfefferkorn M et al (2010) Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol 105: 1430–1436

    Article  PubMed  CAS  Google Scholar 

  14. Hyams J, Walters TD, Crandall W et al (2011) Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn’s disease in childen: REACH open-label extension. Curr Med Res Opin 27: 651–662

    Article  PubMed  CAS  Google Scholar 

  15. Kardorff R, Radke M (2008) Chronisch entzündliche Darmerkrankungen. Pädiatrie 3 („up2date“): 13–44

  16. Mahadevan U, Cucchiara S, Hyams J et al (2011) The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and Colitis Organization. Am J Gastroenterol 206: 214–223

    Article  Google Scholar 

  17. McGinnis JK, Murray KF (2008) Infliximab for ulcerative colitis in children and adolescents. J Clin Gastroenterol 42: 875–879

    Article  PubMed  CAS  Google Scholar 

  18. Pfefferkorn M, Burke G, Griffith A et al (2009) Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 48: 168–174

    Article  PubMed  CAS  Google Scholar 

  19. Rosh JR, Gross T, Mamula P (2007) Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn’s disease: a cautionary tale? Inflamm Bowel Dis 13: 1024–1030

    Article  PubMed  Google Scholar 

  20. Rosh JR, Markowitz J, Goli SR (2008) Retrospective evaluation of the safety and effect of adalimumab therapy (reseat) in pediatric Crohn’s disease. Gastroenterology 134: A657

    Article  Google Scholar 

  21. Ruemmele FM, Lachaux A, Cézard J-P, Morali A et al (2009) Efficacy of infliximab in pediatric Crohn’s disease: A randomized multicenter open-label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis 15: 388–394

    Article  PubMed  Google Scholar 

  22. Ruemmele FM (2010) Pediatric inflammatory bowel diseases: coming of age. Curr Opin Gastroenterol 26: 332–336

    Article  PubMed  Google Scholar 

  23. Russell RK, Wilson ML, Loganathan S et al (2011) A British Society of Peadiatric Gastroenterology, Hepatology and Nutrition survey of the effectiveness and safety of adalimumab in children with inflammatory bowel disease. Aliment Pharmacol Ther 33: 946–953

    Article  PubMed  CAS  Google Scholar 

  24. Rutgeerts P, Feagan BG, Lichtenstein GR (2004) Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology 126: 402–413

    Article  PubMed  CAS  Google Scholar 

  25. Sinitsky DM, Lemberg DA, Leach ST, Bohane TD, Jackson R, Day AS (2010) Infliximab improves inflammation and anthropometric measures in pediatric Crohn’s disease. J Gastroenterol Hepatol 25: 810–816

    Article  PubMed  CAS  Google Scholar 

  26. Timmer A, Behrens R, Buderus S et al (2011) Childhood onset inflammatory bowel disease: predictors of delayed diagnosis from the CEDATA german-language pediatric inflammatory bowel disease registry. J Pediatr 158: 467–473

    Article  PubMed  Google Scholar 

  27. Turner D, Griffith AM (2011) Acute severe ulcerative colitis in children: a systematic review. Inflamm Bowel Dis 17: 440–449

    Article  PubMed  Google Scholar 

  28. Vermeire S, Noman M, Assche GV van et al (2007) Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut 56: 1226–1231

    Article  PubMed  CAS  Google Scholar 

  29. Walters TD, Gilman AR, Griffiths AM (2007) Linear growth improves during Infliximab therapy in children with chronically active severe Crohn’s disease. Inflamm Bowel Dis 13: 424–430

    Article  PubMed  Google Scholar 

  30. Wynands J, Belbouab R, Candon S et al (2008) 12-month follow-up after succesful infliximab therapy in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 46: 293–298

    Article  PubMed  CAS  Google Scholar 

  31. Wyneski MJ, Green A, Kay M et al (2008) Safety and efficacy of adalimumab in pediatric patients with Crohn disease. J Pediatr Gastroenterol Nutr 47: 19–25

    Article  PubMed  CAS  Google Scholar 

Download references

Interessenkonflikt

Der Autor weist auf folgende Beziehungen hin: Mitglied im Advisory Board für chronisch entzündliche Darmerkrankungen im Kindesalter der Fa. MSD sowie Referententätigkeit für die Firmen MSD, Falk und Abbott.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to M. Radke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Radke, M. Behandlung chronisch entzündlicher Darmerkrankungen bei Kindern und Jugendlichen. Gastroenterologe 6, 486–495 (2011). https://doi.org/10.1007/s11377-010-0513-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11377-010-0513-x

Schlüsselwörter

Keywords

Navigation